##  [Investors Annual Results - Cover tab](/node/642611 "Investors Annual Results - Cover tab") 

  



## Annual results 2024 - January 31, 2025

### Press release

[English (PDF 0.4 MB)](/sites/novartis_com/files/q4-2024-media-release-en.pdf) | [Deutsch (PDF 0.4 MB)](/sites/novartis_com/files/q4-2024-media-release-de.pdf)

[Condensed financial report (PDF 0.5 MB)](/sites/novartis_com/files/2025-01-interim-financial-report-en.pdf)

### Webcast and presentation

[Watch the webcast](https://edge.media-server.com/mmc/p/7vboajm5/)

[Download the podcast (MP3 30 MB)](/sites/novartis_com/files/2025-02/q4-2024-investor-presentation.mp3)

[Download the presentation (PDF 4.7 MB)](/sites/novartis_com/files/q4-2024-investor-presentation.pdf)

[Read the transcript](/investors/financial-data/quarterly-results/2024-q4-and-full-year-results-transcript "2024 Q4 and full year results presentation and transcript")

[Novartis Q4 2024 impact and sustainability update (PDF 1.0 MB)](/sites/novartis_com/files/novartis-q4-2024-impact-and-sustainability-update.pdf)

[Download 2025 epidemiology data (PDF 2.0 MB)](/sites/novartis_com/files/novartis-target-patient-populations-2025.pdf)

---



 



 ![Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida](/sites/novartis_com/files/styles/cta_image/public/2025-01/portrait-of-kate-kostelyk-and-her-labrador.jpg?h=ba8c19bb&itok=3Ib08wIG "Kate Kostelyk, IgA nephropathy (IgAN) patient, and her labrador Dakoda in Mims, Florida") 

 

##  Novartis in Society Integrated Report 2024 

This report covers our business, strategy and performance. It highlights progress against our ESG targets and describes how we create sustainable value for diverse stakeholders. It follows requirements of the Swiss Code of Obligations and various voluntary reporting frameworks and standards.

[English (PDF 5.0 MB)](/sites/novartis_com/files/novartis-integrated-report-2024.pdf) | [German (PDF 4.7 MB)](/sites/novartis_com/files/novartis-integrated-report-2024-de.pdf)



 

 



 





 ![Prof. Dr. Ulf Landmesser (center) at the Charité hospital in Berlin, Germany](/sites/novartis_com/files/styles/cta_image/public/2025-01/prof-dr-ulf-landmesser-at-charite-hospital-berlin-germany.jpg?h=0e12c38e&itok=gAgoO6a8 "Prof. Dr. Ulf Landmesser (center) at the Charité hospital in Berlin, Germany") 

 

##  Annual Report 2024 and US Securities & Exchange Commission Form 20-F 2024 

These reports provide a comprehensive overview of Novartis, including our company structure, corporate governance, operating and financial results, and compensation practices. They are filed with the SIX Swiss Exchange in Switzerland and the Securities and Exchange Commission in the US.

[Annual Report 2024 (PDF 3.5 MB)](/sites/novartis_com/files/novartis-annual-report-2024.pdf) | [Form 20-F 2024 (PDF 3.4 MB)](/sites/novartis_com/files/novartis-20-f-2024.pdf)



 

 [Order the publications](/news/stay-up-to-date "Order the publications") 



 

 



 





 



- [Print](/node/642611/printable/print)
- [PDF](/node/642611/printable/pdf)